Analysts Issue Forecasts for CVRx FY2025 Earnings

CVRx, Inc. (NASDAQ:CVRX) – Cantor Fitzgerald issued their FY2025 earnings estimates for CVRx in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($1.58) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 price target on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.61) per share.

Several other brokerages have also issued reports on CVRX. Canaccord Genuity Group raised their target price on CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Craig Hallum raised their price objective on shares of CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Lake Street Capital raised their price target on shares of CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, William Blair upgraded CVRx from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, CVRx currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

CVRx Stock Performance

Shares of CVRx stock opened at $17.21 on Wednesday. The business’s fifty day simple moving average is $14.27 and its 200 day simple moving average is $11.25. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. CVRx has a 12 month low of $6.40 and a 12 month high of $29.23. The firm has a market capitalization of $417.51 million, a P/E ratio of -6.37 and a beta of 1.26.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The firm had revenue of $13.37 million for the quarter, compared to the consensus estimate of $13.28 million. CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. During the same period in the prior year, the business earned ($0.43) EPS.

Institutional Trading of CVRx

Several hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in CVRx in the 3rd quarter worth approximately $108,000. XTX Topco Ltd bought a new position in shares of CVRx in the third quarter worth $150,000. Jane Street Group LLC boosted its holdings in shares of CVRx by 36.1% in the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after acquiring an additional 5,053 shares during the period. Barclays PLC grew its position in shares of CVRx by 312.5% in the third quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after purchasing an additional 14,445 shares in the last quarter. Finally, Centiva Capital LP bought a new stake in shares of CVRx during the 3rd quarter valued at $178,000. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.